L-Arginine supplementation in sepsis

Beneficial or harmful?

Andre C Kalil, Robert L. Danner

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Recent results are reviewed on the effects of L-arginine supplements in excess of standard nutritional practices during severe sepsis and septic shock. RECENT FINDINGS: Septic shock has been alternatively viewed as an L-arginine-deficient state or as a syndrome caused by excess nitric oxide, a vasoactive product of L-arginine metabolism. L-Arginine has many physiologic and pharmacologic effects that indicate its potential to affect survival in septic patients. Animal studies have documented immunologic effects of L-arginine and of commercial 'immune-enhancing' diets. However, survival studies in small animals have not consistently favored L-arginine. L-Arginine monotherapy in a canine model of septic shock found significant harm at infusion rates of less than twice that administered in standard formulations of total parenteral nutrition. Meanwhile, clinical studies have suffered from lack of statistical power, patient heterogeneity, randomization failures, and use of complex nutritional formulas. Meta-analyses have noted heterogeneity between the effects of immune-enhancing diets in surgical versus medical patients and mixed critically ill populations that include subjects with sepsis, indicating that these results may not be reliably pooled. SUMMARY: To date, published evidence has not established the safety and efficacy of L-arginine at doses above standard dietary practices in severe sepsis or septic shock.

Original languageEnglish (US)
Pages (from-to)303-308
Number of pages6
JournalCurrent Opinion in Critical Care
Volume12
Issue number4
DOIs
StatePublished - Aug 1 2006

Fingerprint

Arginine
Sepsis
Septic Shock
Diet
Survival
Total Parenteral Nutrition
Random Allocation
Critical Illness
Meta-Analysis
Canidae
Nitric Oxide
Safety
Population

Keywords

  • Enteral
  • L-arginine
  • Parenteral
  • Sepsis
  • Septic shock
  • Severe sepsis

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

L-Arginine supplementation in sepsis : Beneficial or harmful? / Kalil, Andre C; Danner, Robert L.

In: Current Opinion in Critical Care, Vol. 12, No. 4, 01.08.2006, p. 303-308.

Research output: Contribution to journalReview article

@article{094b73a11368463888eb49ef8006ef92,
title = "L-Arginine supplementation in sepsis: Beneficial or harmful?",
abstract = "PURPOSE OF REVIEW: Recent results are reviewed on the effects of L-arginine supplements in excess of standard nutritional practices during severe sepsis and septic shock. RECENT FINDINGS: Septic shock has been alternatively viewed as an L-arginine-deficient state or as a syndrome caused by excess nitric oxide, a vasoactive product of L-arginine metabolism. L-Arginine has many physiologic and pharmacologic effects that indicate its potential to affect survival in septic patients. Animal studies have documented immunologic effects of L-arginine and of commercial 'immune-enhancing' diets. However, survival studies in small animals have not consistently favored L-arginine. L-Arginine monotherapy in a canine model of septic shock found significant harm at infusion rates of less than twice that administered in standard formulations of total parenteral nutrition. Meanwhile, clinical studies have suffered from lack of statistical power, patient heterogeneity, randomization failures, and use of complex nutritional formulas. Meta-analyses have noted heterogeneity between the effects of immune-enhancing diets in surgical versus medical patients and mixed critically ill populations that include subjects with sepsis, indicating that these results may not be reliably pooled. SUMMARY: To date, published evidence has not established the safety and efficacy of L-arginine at doses above standard dietary practices in severe sepsis or septic shock.",
keywords = "Enteral, L-arginine, Parenteral, Sepsis, Septic shock, Severe sepsis",
author = "Kalil, {Andre C} and Danner, {Robert L.}",
year = "2006",
month = "8",
day = "1",
doi = "10.1097/01.ccx.0000235206.92697.bf",
language = "English (US)",
volume = "12",
pages = "303--308",
journal = "Current Opinion in Critical Care",
issn = "1070-5295",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - L-Arginine supplementation in sepsis

T2 - Beneficial or harmful?

AU - Kalil, Andre C

AU - Danner, Robert L.

PY - 2006/8/1

Y1 - 2006/8/1

N2 - PURPOSE OF REVIEW: Recent results are reviewed on the effects of L-arginine supplements in excess of standard nutritional practices during severe sepsis and septic shock. RECENT FINDINGS: Septic shock has been alternatively viewed as an L-arginine-deficient state or as a syndrome caused by excess nitric oxide, a vasoactive product of L-arginine metabolism. L-Arginine has many physiologic and pharmacologic effects that indicate its potential to affect survival in septic patients. Animal studies have documented immunologic effects of L-arginine and of commercial 'immune-enhancing' diets. However, survival studies in small animals have not consistently favored L-arginine. L-Arginine monotherapy in a canine model of septic shock found significant harm at infusion rates of less than twice that administered in standard formulations of total parenteral nutrition. Meanwhile, clinical studies have suffered from lack of statistical power, patient heterogeneity, randomization failures, and use of complex nutritional formulas. Meta-analyses have noted heterogeneity between the effects of immune-enhancing diets in surgical versus medical patients and mixed critically ill populations that include subjects with sepsis, indicating that these results may not be reliably pooled. SUMMARY: To date, published evidence has not established the safety and efficacy of L-arginine at doses above standard dietary practices in severe sepsis or septic shock.

AB - PURPOSE OF REVIEW: Recent results are reviewed on the effects of L-arginine supplements in excess of standard nutritional practices during severe sepsis and septic shock. RECENT FINDINGS: Septic shock has been alternatively viewed as an L-arginine-deficient state or as a syndrome caused by excess nitric oxide, a vasoactive product of L-arginine metabolism. L-Arginine has many physiologic and pharmacologic effects that indicate its potential to affect survival in septic patients. Animal studies have documented immunologic effects of L-arginine and of commercial 'immune-enhancing' diets. However, survival studies in small animals have not consistently favored L-arginine. L-Arginine monotherapy in a canine model of septic shock found significant harm at infusion rates of less than twice that administered in standard formulations of total parenteral nutrition. Meanwhile, clinical studies have suffered from lack of statistical power, patient heterogeneity, randomization failures, and use of complex nutritional formulas. Meta-analyses have noted heterogeneity between the effects of immune-enhancing diets in surgical versus medical patients and mixed critically ill populations that include subjects with sepsis, indicating that these results may not be reliably pooled. SUMMARY: To date, published evidence has not established the safety and efficacy of L-arginine at doses above standard dietary practices in severe sepsis or septic shock.

KW - Enteral

KW - L-arginine

KW - Parenteral

KW - Sepsis

KW - Septic shock

KW - Severe sepsis

UR - http://www.scopus.com/inward/record.url?scp=33746096538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746096538&partnerID=8YFLogxK

U2 - 10.1097/01.ccx.0000235206.92697.bf

DO - 10.1097/01.ccx.0000235206.92697.bf

M3 - Review article

VL - 12

SP - 303

EP - 308

JO - Current Opinion in Critical Care

JF - Current Opinion in Critical Care

SN - 1070-5295

IS - 4

ER -